View in EDS PDF Full Text

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.
Authors: Pousse L; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland., Korfi K; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland., Medeiros BC; Genentech, Inc. Hematology Department, South San Francisco, CA, United States., Berrera M; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel (RICB), Basel, Switzerland., Kumpesa N; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel (RICB), Basel, Switzerland., Eckmann J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Münich (RICM), Penzberg, Germany., Hutter IK; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland., Griesser V; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel (RICB), Basel, Switzerland., Karanikas V; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland., Klein C; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland., Amann M; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.
Source: Frontiers in oncology [Front Oncol] 2023 May 02; Vol. 13, pp. 1150149. Date of Electronic Publication: 2023 May 02 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37205201
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pousse+L%22">Pousse L</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Korfi+K%22">Korfi K</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Medeiros+BC%22">Medeiros BC</searchLink>; Genentech, Inc. Hematology Department, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Berrera+M%22">Berrera M</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel (RICB), Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kumpesa+N%22">Kumpesa N</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel (RICB), Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Eckmann+J%22">Eckmann J</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Münich (RICM), Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Hutter+IK%22">Hutter IK</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Griesser+V%22">Griesser V</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel (RICB), Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Karanikas+V%22">Karanikas V</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Klein+C%22">Klein C</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.<br /><searchLink fieldCode="AU" term="%22Amann+M%22">Amann M</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich (RICZ), Schlieren, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2023 May 02; Vol. 13, pp. 1150149. <i>Date of Electronic Publication: </i>2023 May 02 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37205201
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2023.1150149
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1150149
    Titles:
      – TitleFull: CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pousse L
      – PersonEntity:
          Name:
            NameFull: Korfi K
      – PersonEntity:
          Name:
            NameFull: Medeiros BC
      – PersonEntity:
          Name:
            NameFull: Berrera M
      – PersonEntity:
          Name:
            NameFull: Kumpesa N
      – PersonEntity:
          Name:
            NameFull: Eckmann J
      – PersonEntity:
          Name:
            NameFull: Hutter IK
      – PersonEntity:
          Name:
            NameFull: Griesser V
      – PersonEntity:
          Name:
            NameFull: Karanikas V
      – PersonEntity:
          Name:
            NameFull: Klein C
      – PersonEntity:
          Name:
            NameFull: Amann M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 05
              Text: 2023 May 02
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1